Giant Cell Arteritis Clinical Trial
Official title:
VCRC Genetic Repository One-Time DNA Protocol
Verified date | June 2024 |
Source | University of Pennsylvania |
Contact | Carol McAlear, MA |
cmcalear[@]upenn.edu | |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels. Results of these studies will provide vasculitis researchers with insight into the causes of these diseases and generate new ideas for diagnostic tests and therapies, and will be of great interest to the larger communities of researchers investigating vasculitis and other autoimmune, inflammatory, and vascular diseases.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | August 2027 |
Est. primary completion date | August 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years and older |
Eligibility | Inclusion Criteria: 1. Diagnostic criteria for Giant Cell Arteritis Age at disease onset >50 years (required) 1. New onset or new type of localized pain in the head 2. Temporal artery abnormality (i.e. temporal artery tenderness to palpation or decreased pulsation, unrelated to arteriosclerosis of cervical arteries) 3. ESR of >40mm in the first hour by the Westergren method 4. Abnormal artery biopsy (i.e. temporal artery biopsy showing vasculitis characterized by a predominance of mononuclear cell infiltration or granulomatous inflammation, usually with multinucleated giant cells) 5. Large Vessel Vasculitis (LVV) by angiogram or biopsy not explained by something else Inclusion Criteria: 2. Diagnostic criteria for Takayasu's Arteritis 1. Age at disease onset <50 years 2. Claudication of extremities 3. Decreased brachial artery pulse (one or both arteries) 4. Blood pressure difference of >10mm Hg between the arms 5. Bruit over subclavian arteries or aorta 6. Arteriogram abnormalities compatible with TAK (includes conventional dye angiography or MR angiography or CT angiography) Inclusion Criteria: 3. Diagnostic criteria for Polyarteritis Nodosa Major criteria (not explained by other causes) felt by investigator to be due to vasculitis 1. Arteriographic abnormality 2. Presence of granulocyte or mixed leukocyte infiltrate in an arterial wall on biopsy 3. Mononeuropathy or polyneuropathy Minor criteria (not explained by other causes) felt by investigator to be due to vasculitis 1. Weight loss > 4 kg 2. Livedo reticularis, cutaneous ulcerations, or skin nodules 3. Testicular pain or tenderness 4. Myalgias 5. Diastolic blood pressure > 90 mm Hg 6. Elevated BUN or serum creatinine levels 7. Ischemic abdominal pain Isolated cutaneous Polyarteritis Nodosa 1. Biopsy-proven cutaneous PAN Inclusion Criteria: 4. Diagnostic criteria for Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangitis (MPA) - Diagnosis of GPA or MPA. Widely accepted diagnostic criteria, as opposed to classification criteria or definitions, have not been developed for GPA & MPA. - For diagnosis of GPA meets at least 2 of the following 5 modified ACR criteria: 1. Nasal or oral inflammation with oral ulcers or nasal discharge with pus or blood 2. Abnormal chest radiograph with nodules, fixed infiltrates, or cavities 3. Urinary sediment with microhematuria or red cell casts 4. Granulomatous inflammation within the wall of an artery or in the perivascular area on biopsy 5. Antineutrophil cytoplasmic antibody (ANCA) positive by enzyme immunoassay for either PR3- or MPO-ANCA - For diagnosis of MPA, meets the Chapel Hill Consensus Conference Definition for MPA: 1. Necrotizing vasculitis, with few or no immune deposits, that affects small vessels (i.e., capillaries, venules, arterioles) 2. Necrotizing arteritis involving small- and medium-sized arteries may be present 3. Necrotizing glomerulonephritis is very common 4. Pulmonary capillaritis often occurs Inclusion Criteria: 5. Diagnostic criteria for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) 1. Asthma 2. Peak peripheral blood eosinophilia of >10% of total WBC 3. Peripheral neuropathy attributable to vasculitis 4. Transient pulmonary infiltrates on chest imaging studies 5. Paranasal sinus abnormalities or nasal polyposis 6. Eosinophilic inflammation on tissue biopsy If patients have 4 of the above 6 criteria but lack clearcut documentation of small vessel vasculitis, they are also eligible for enrollment. General Exclusion Criteria: - Inability to give informed consent and to sign the consent form - Enrolled in VCRC protocols 5502, 5503, 5504, 5505, 5506, 5522, or 5523 - Unwilling to provide blood for DNA collection |
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Healthcare | Hamilton | Ontario |
Canada | Mount Sinai Hospital | Toronto | Ontario |
Turkey | Istanbul University | Istanbul | Fatih |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Northwestern University | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
United States | Hospital for Special Surgery | New York | New York |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | Mayo Clinic | Rochester | Minnesota |
United States | University of Utah | Salt Lake City | Utah |
United States | University of California, San Francisco | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of Pennsylvania | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Rare Diseases (ORD), Rare Diseases Clinical Research Network |
United States, Canada, Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of clinical data and linked DNA specimens. | 1 year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03812302 -
Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)
|
Phase 2 | |
Recruiting |
NCT02257866 -
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
|
||
Recruiting |
NCT04888221 -
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
|
Phase 3 | |
Recruiting |
NCT05380453 -
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
|
Phase 3 | |
Recruiting |
NCT02333708 -
Study of Circulating Microparticles in Giant Cell Arteritis
|
||
Completed |
NCT01450137 -
Tocilizumab for Patients With Giant Cell Arteritis
|
Phase 2 | |
Completed |
NCT03827018 -
KPL-301 for Subjects With Giant Cell Arteritis
|
Phase 2 | |
Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
Recruiting |
NCT04239196 -
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA
|
Phase 2 | |
Recruiting |
NCT06460142 -
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
|
||
Completed |
NCT03202368 -
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)
|
Phase 3 | |
Not yet recruiting |
NCT02523625 -
Giant Cell Arteritis: Improving Use of Ultrasound Evaluation
|
N/A | |
Completed |
NCT03285945 -
FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment
|
N/A | |
Completed |
NCT02190916 -
Vasculitis Illness Perception (VIP) Study
|
N/A | |
Terminated |
NCT02531633 -
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
|
Phase 3 | |
Completed |
NCT03765424 -
Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
|
||
Completed |
NCT03409913 -
Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA
|
N/A | |
Completed |
NCT01910038 -
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
|
Phase 2 | |
Not yet recruiting |
NCT04012905 -
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
|
Phase 3 | |
Recruiting |
NCT06004154 -
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
|